Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 20/20 | 0.68 |
| ▸ | BCL2 | P10415 | 16/20 | 0.68 |
| ▸ | BCL2L2 | Q92843 | 5/20 | 0.59 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.57 |
| ▸ | ALB | P02768 | 1/20 | 0.55 |
| ▸ | MDM4 | O15151 | 1/20 | 0.52 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | BID | P55957 | 1/20 | 0.52 |
| ▸ | BAX | Q07812 | 1/20 | 0.52 |
| ▸ | ASPH | Q12797 | 1/20 | 0.52 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.52 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.52 |
| ▸ | BAD | Q92934 | 1/20 | 0.52 |
| ▸ | BBC3 | Q9BXH1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2948805 | 0.90 | BCL2L1 (0.68) | BCL2L1BCL2BCL2L2MCL1ALB | |
| SCHEMBL2949893 | 0.89 | BCL2L1 (0.65) | BCL2L1BCL2BCL2L2MCL1ALB | |
| SCHEMBL2947604 | 0.89 | BCL2L1 (0.74) | BCL2L1BCL2BCL2L2MCL1ALB | |
| SCHEMBL2943837 | 0.86 | BCL2L1 (0.75) | BCL2L1BCL2BCL2L2MCL1ALB | |
| SCHEMBL2949345 | 0.85 | BCL2L1 (0.63) | BCL2L1BCL2BCL2L2MCL1ALB | |
| SCHEMBL2951595 | 0.85 | BCL2L1 (0.63) | BCL2L1BCL2BCL2L2MCL1ALB | |
| SCHEMBL2950524 | 0.84 | BCL2L1 (0.69) | BCL2L1BCL2BCL2L2MCL1ALB | |
| SCHEMBL2951384 | 0.83 | BCL2L1 (0.65) | BCL2L1BCL2BCL2L2MCL1ALB | |
| SCHEMBL2026719 | 0.82 | BCL2L1 (0.74) | BCL2L1BCL2BCL2L2MCL1MDM4 | |
| SCHEMBL2949684 | 0.82 | BCL2L1 (0.70) | BCL2L1BCL2BCL2L2MCL1ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754886-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | US | disclosed |
| US-7504512-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1318978-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | ABBVIE INC. | 2004-09-30 | — | — | US | disclosed |
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | BCL2L1 4/4885BCL2 3/4885BCL2L2 18/4885 |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | BCL2L1 5/4885BCL2 3/4885BCL2L2 19/4885 |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BCOR | BCL2L1 6/4885BCL2 2/4885BCL2L2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.